Experimental
Resveratrol
The prediction game
Call it: rising or fading?
Where does Resveratrol stand 12 months from now? Lock your call with a confidence level. When the window closes, the Brier rule scores your calibration: right and confident earns the most, wrong and confident costs the most. Points and a leaderboard spot are the whole prize. No stakes, no money.
One call per intervention. It locks the moment you submit: no edits, no cancels. It resolves when the 12-month window closes.
The Crowd’s Call
Rising or fading over the next 12 months? Lock your call and find out if you saw it coming.
Community Signal
No weigh-ins yet. Be the first and set the early signal.
Evidence
Evidence grade: E (thin evidence)
Graded from the strength of the published research, independent of any verdict on this page.
Evidence Anchor
BioHarmony 5.6/10
Resveratrol may be worth a trial for postmenopausal women focused on modest cognitive or cerebrovascular gains and for high-risk adults who need a cheap, low-effort supplement to support marginal cardiometabolic markers, but the evidence does not support broad longevity or SIRT1 activation claims. Large meta-analyses of human trials found no overall effect on SIRT1 expression or protein levels, limiting expectations for a systemic anti-aging impact [Mansouri 2025](https://pubmed.ncbi.nlm.nih.gov/40158656/). Small subgroup signals appear in postmenopausal lipid profiles and cognition, as shown in a 24-month crossover study [Thaung Zaw 2020](https://pubmed.ncbi.nlm.nih.gov/32900519/). Oral bioavailability rises with dose but remains highly variable across formulations, tempering confidence in consistent physiological exposure [Szymkowiak 2025](https://pubmed.ncbi.nlm.nih.gov/39557444/). ✅ Best for: Older adults with impaired glucose tolerance who want a low-cost adjunct after diet, exercise, sleep, glucose monitoring, and medication basics are handled. Postmenopausal women specifically targeting cerebrovascular and cognitive endpoints, willing to run the 75 mg twice-daily, long-duration pattern from Thaung Zaw 2020 under clinician supervision. Patients with cardiovascular-risk markers who understand the evidence is marker-level, not outcomes-level, and who are not using warfarin, high-risk antiplatelet stacks, rosuvastatin, topotecan, or hormone-sensitive cancer therapy. ❌ Avoid if: You have multiple myeloma, chronic kidney disease, reduced renal reserve, transplant history, anticoagulant therapy, active hormone-sensitive cancer treatment, HER2-positive or ERalpha-positive breast cancer concerns, BRCA-related high-risk monitoring, pregnancy, lactation, or pediatric use. Avoid during exercise blocks where VO2max, blood-pressure adaptation, or hypertrophy is the goal, because Gliemann 2013 found blunted training adaptations. Healthy non-obese biohackers seeking longevity, glucose optimization, or a SIRT1 lever should skip it.
Read the full BioHarmony report
My score and my verdict: one signal of three, never the whole answer.
Momentum
Signals begin with Edition 2
Direction needs two weekly snapshots to compare, so the arrows stay off until the next edition. Attention tracking is already running.
Momentum = how fast attention is rising across search, Reddit, PubMed, podcasts, and curated industry newsletters this week; it can flag an item as Overhyped/Fading, but it never overrides the evidence behind Proven. How momentum works.
- Ring
- Experimental
- Trend
- Begins with Edition 2
- Momentum
- 6.2%
- BioHarmony Score
- 5.6/10
- Last Updated
- Jul 2, 2026
Sources
- BioHarmony score
- Search trend delta
- Reddit velocity
- PubMed publication count
- Podcast mention frequency
- Curated newsletter mentions
The score anchors the ring; the other five drive momentum, which can nudge the ring by one step at most. How placement works.
Weigh In
Your input feeds the community signal shown beside my verdict. It informs the board and it never sets the score by itself. How community input works.
New voice here? We send a one-tap verification link so every entry comes from a real person. Signed-in members skip this.